Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided AI response’s core claim (“WARNING: SEVERE NEUTROPENIA AND SEVERE DIARRHEA”) is directly supported by the supplied FDA label excerpts in Sections 5.1 and 5.2 (including the boxed/warning-style wording provided), with no stated contradictions.
Category Scores
Accurate Statements
WARNING: SEVERE NEUTROPENIA AND SEVERE DIARRHEA is supported by the ONIVYDE prescribing information.
Supported by label excerpts: Section 5.1 (severe/life-threatening neutropenia, fatal neutropenic sepsis; ANC withholding guidance) and Section 5.2 (severe/life-threatening diarrhea; bowel obstruction; withholding for Grade 2-4).
Unsupported Statements
Onivyde customer assistance programs are available to help eligible patients access and afford the medication.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Onivyde customer assistance programs are typically offered by the manufacturer of Onivyde.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Onivyde patient assistance programs may offer co-pay assistance.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Onivyde patient assistance programs may offer free medication for uninsured or underinsured patients.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Onivyde patient assistance programs may offer other support services.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Eligibility requirements and program details for Onivyde patient assistance programs can vary.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
To apply for Onivyde assistance, personal information including medical diagnosis, insurance status, and financial information may be required to determine eligibility.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Onivyde coverage by insurance plans can differ.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Many insurance providers offer some level of coverage of Onivyde.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Out-of-pocket costs for Onivyde can still be significant.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Patient assistance programs can help reduce out-of-pocket costs for people with high co-pays or who are uninsured.
Not supported or addressed by the provided ONIVYDE prescribing information excerpts.
Contradictions
Important Omissions
No label management details (e.g., ANC threshold, withholding/resume/reduction specifics; diarrhea pattern and specific prevention/atropine/loperamide guidance) were included as part of the single broad warning claim.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The only safety-related claim evaluated (severe neutropenia and severe diarrhea warnings) is consistent with the provided label excerpts. The other statements concern assistance/insurance and are not label-based.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Several non-label claims about patient assistance/insurance and associated application details are not supported by the provided prescribing information excerpts.
Suggested Improvement
Limit evaluation and statements to content present in the FDA-approved label; for warning statements, include only label-supported specifics (e.g., section citations or exact management language) when making safety-related claims.